Evidence map›Paper›PMID 27046792›Full record

ArticleToxicology2016

Characterization of cytoprotective and toxic properties of iron chelator SIH, prochelator BSIH and their degradation products.

Hana Jansová, Jan Bureš, Miloslav Macháček, Pavlína Hašková, Anna Jirkovská, Jaroslav Roh, Qin Wang, Katherine J Franz, Petra Kovaříková, Tomáš Šimůnek

Open access · greenAbstract read
In one paragraph

Article in Toxicology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Potential Treatment of Retinal Diseases with Iron Chelators.Pharmaceuticals (Basel, Switzerland) · 2018
    Review
  7. The hydrolytic susceptibility of prochelator BSIH in aqueous solutions.Bioorganic & medicinal chemistry letters · 2017
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Hana JansováFaculty of Pharmacy, Charles University in Prague, 500 05 Hradec Králové, Czech Republic.
Jan BurešFaculty of Pharmacy, Charles University in Prague, 500 05 Hradec Králové, Czech Republic.
Miloslav MacháčekFaculty of Pharmacy, Charles University in Prague, 500 05 Hradec Králové, Czech Republic.
Pavlína HaškováFaculty of Pharmacy, Charles University in Prague, 500 05 Hradec Králové, Czech Republic.
Anna JirkovskáFaculty of Pharmacy, Charles University in Prague, 500 05 Hradec Králové, Czech Republic.
Jaroslav RohFaculty of Pharmacy, Charles University in Prague, 500 05 Hradec Králové, Czech Republic.
Qin WangDepartment of Chemistry, Duke University, Durham, NC 22708, USA.
Katherine J FranzDepartment of Chemistry, Duke University, Durham, NC 22708, USA.
Petra KovaříkováFaculty of Pharmacy, Charles University in Prague, 500 05 Hradec Králové, Czech Republic.
Tomáš ŠimůnekFaculty of Pharmacy, Charles University in Prague, 500 05 Hradec Králové, Czech Republic. Electronic address: Tomas.Simunek@faf.cuni.cz.
Charles University · CZDuke University · US

Funding

Metals, Drugs and Fungal PathogensR01GM084176 · NIGMS · DUKE UNIVERSITY · PI FRANZ, KATHERINE J. · 2008 to 2021
$4.3M
NIGMS NIH HHS R01 GM084176
6 · The paper itself

Abstract

Free cellular iron catalyzes the formation of toxic hydroxyl radicals and therefore chelation of iron could be a promising therapeutic approach in pathological states associated with oxidative stress. Salicylaldehyde isonicotinoyl hydrazone (SIH) is a strong intracellular iron chelator with well documented potential to protect against oxidative damage both in vitro and in vivo. Due to the short biological half-life of SIH and risk of toxicity due to iron depletion, boronate prochelator BSIH has been designed. BSIH cannot bind iron until it is activated by certain reactive oxygen species to active chelator SIH. The aim of this study was to examine the toxicity and cytoprotective potential of BSIH, SIH, and their decomposition products against hydrogen peroxide-induced injury of H9c2 cardiomyoblast cells. Using HPLC, we observed that salicylaldehyde was the main decomposition products of SIH and BSIH, although a small amount of salicylic acid was also detected. In the case of BSIH, the concentration of formed salicylaldehyde consistently exceeded that of SIH. Isoniazid and salicylic acid were not toxic nor did they provide any antioxidant protective effect in H9c2 cells. In contrast, salicylaldehyde was able to chelate intracellular iron and significantly preserve cellular viability and mitochondrial inner membrane potential induced by hydrogen peroxide. However it was consistently less effective than SIH. The inherent toxicities of salicylaldehyde and SIH were similar. Hence, although SIH - the active chelating agent formed following the BSIH activation - undergoes rapid hydrolysis, its principal decomposition product salicylaldehyde accounts markedly for both cytoprotective and toxic properties.

Indexed as

AldehydesAnimalsBoronic AcidsCell LineCell SurvivalChromatography, High Pressure LiquidHalf-LifeHydrazonesHydrogen PeroxideIronIron Chelating AgentsIsonicotinic AcidsMembrane Potential, MitochondrialMyoblasts, CardiacOxidative StressRatsAldehydesBoronic AcidsHydrazonesHydrogen PeroxideIronIron Chelating Agents(isonicotinic acid (2-(4,4,5,5-tetramethyl-(1,3,2)dioxaborolan-2-yl)benzylidene)hydrazide)Isonicotinic AcidsReactive Oxygen Speciessalicylaldehyde isonicotinoyl hydrazoneBoronyl salicylaldehyde isonicotinoyl hydrazone (BSIH)Iron chelationProchelatorSalicylaldehydeSalicylaldehyde isonicotinoyl hydrazone (SIH)

Identifiers

PMID27046792
PMCPMC4889448
OpenAlexW2318162280

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.